| Literature DB >> 29843605 |
Benshui Shu1,2, Jianwen Jia1, Jingjing Zhang1, Veeran Sethuraman1, Xin Yi1, Guohua Zhong3,4.
Abstract
BACKGROUND: Azadirachtin, one of the most promising botanical insecticides, has been widely used for pest control. Azadirachtin induces apoptosis in insect cell lines, including Sf9, SL-1 and BTI-Tn-5B1-4. Mitochondrial and lysosomal pathways are likely involved in the azadirachtin-induced apoptosis, however, detailed molecular mechanisms remain largely undefined.Entities:
Keywords: 2-DE; Apoptosis; Azadirachtin; RNAi; Sf-DnaJ1
Mesh:
Substances:
Year: 2018 PMID: 29843605 PMCID: PMC5975434 DOI: 10.1186/s12864-018-4801-z
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1The analysis of proliferation inhibition and apoptosis induction by azadirachtin in Sf9 cells. a Cell viability of Sf9 cells after treated with multiple concentrations of azadirachtin for 24 h. b Morphological changes in Sf9 cells treated with 0.75 μg/mL azadirachtin at different times. c Cell nucleus morphology was detected by Hoechst 33258 staining. d The detection of Caspase-3 like activity in Sf9 cells after 0.75 μg/mL azadirachtin treatment for multiple time points. Different letters above bars indicate significant differences between different treatments by ANOVA followed by DMRT test (P < 0.05)
Fig. 2The two-dimensional electrophoresis images of azadirachtin-treated Sf9 cells. a 2-DE gel of control sample. b 2-DE gel of the sample treated with 0.75 μg/mL azadirachtin for 24 h. Arrows indicate the differentially expressed protein spots, which were designated as D1–D11 and U1, U2. Among them, spots D1-D11 are down-regulated and spots U1and U2 are up-regulated
Fig. 3The specific figures of different spots
Identification of differentially expressed proteins in Sf9 cells treated with the azadirachtin by LTQ-MS/MS
| Spot no | Protein name | Fold change a) | NCBI accession number | DP b) | AAC c) | MW | PI | Peptides identified |
|---|---|---|---|---|---|---|---|---|
| D1 | DnaJ homolog subfamily A member 1 | 1.61 ± 0.13 | gi|14053203 | 2 | 2.00 | 45134.93 | 6.38 | SGNDLILR |
| D2 | Ribosomal protein SA | 2.85 ± 0.18 | gi|54609281 | 3 | 7.84 | 33408.77 | 4.87 | FAAHTGATPIAGR |
| D3 | Actin | 8.97 ± 0.21 | gi|46371991 | 6 | 13.70 | 40603.37 | 5.46 | GYSFTTTAER |
| D4 | Actin | 3.21 ± 0.11 | gi|46371991 | 7 | 16.99 | 40603.37 | 5.46 | GYSFTTTAER |
| D5 | Actin | 1.92 ± 0.08 | gi|46371991 | 7 | 16.99 | 40603.37 | 5.46 | GYSFTTTAER |
| D6 | Beta-tubulin | 10.43 ± 0.24 | gi|74275413 | 3 | 10.14 | 33323.12 | 5.9 | EVDEQMLNIQNK |
| D7 | Proteasome zeta subunit | 6.26 ± 0.23 | gi|114050993 | 7 | 36.63 | 26874.64 | 4.98 | LFQVEYAIEAIK |
| D8 | P27BBP/eIF6-like | 3.17 ± 0.14 | gi|82880642 | 4 | 14.69 | 26304.74 | 4.63 | VQFENNNEVGVFSK |
| D9 | Translationally-controlled tumor protein homolog | 2.38 ± 0.16 | gi|74837218 | 10 | 41.86 | 19938.81 | 4.67 | LVETYAFGDKK |
| D11 | Proteasome subunit alpha type 6-A | 1.73 ± 0.07 | gi|114052160 | 3 | 13.41 | 27143 | 6.44 | GTDAAVVAAQR |
| U1 | Ribosomal protein L9 | 5.06 ± 0.19 | gi|112983495 | 6 | 25.79 | 21377.03 | 9.94 | MAPGVTVVNSPK |
| U2 | Abnormal wing disc-like | 2.80 ± 0.22 | gi|153791847 | 5 | 27.92 | 17312.92 | 6.75 | NIIHGSDSVESAK |
a) Fold change: D1-D11: the ratio of protein intensity of CK versus AZA; U1-U2: the ratio of protein intensity of AZA versus CK.
b) Distinct peptides matched. c) Amino acids coverage.
Fig. 4The expression level changes of differentially expressed proteins verified by qRT-PCR and western blot. a The mRNA expression profiles of six differentially expressed proteins in Sf9 cells with azadirachtin treatment for 24 h. Cells that treated with 0.1% DMSO were used as control. The GAPDH gene was used as the reference gene and data are expressed as arithmetic mean ± SEM of three independent experiments. Different letters above bars indicate significant differences between different treatments by ANOVA followed by student’s t test (P < 0.05). b the protein expression changes of DnaJ1 and TCTP in Sf9 cells after azadirachtin treatment for 24 h
Fig. 5Silence of Sf-DnaJ1 enhanced apoptosis induced by azadirachtin. a The relative mRNA expression level changes of Sf-DnaJ1 in Sf9 cells with RNAi treatments. Control, normal cells; negative control, cells treated with unrelated dsRNA. b The protein expression levels of DnaJ1 in Sf9 cells with RNAi treatments. c The effects of RNAi treatments on apoptosis induced by azadirachtin in Sf9 cells were detected by flow cytometry. d The effects of RNAi treatments on apoptotic rate induced by azadirachtin in Sf9 cells. The data represent the mean values± S.E.M of three independent experiments. Different letters above bars indicate significant differences between different treatments at the same time (a represent p < 0.05) by ANOVA followed by DMRT